Insight Molecular Diagnostics (IMDX) Capital Expenditures (2015 - 2026)

Insight Molecular Diagnostics has reported Capital Expenditures for 12 years, with the latest figure at $613000.0 in Q1 2026.

• Quarterly Capital Expenditures rose 99.67% year-over-year to $613000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.5 million (up 336.92% YoY) and the FY2025 annual result came in at $3.2 million, up 517.25% from the prior year.
• Capital Expenditures declined to $613000.0 in Q1 2026 per IMDX's latest filing, from $1.5 million in the prior quarter.
• Over five years, Capital Expenditures peaked at $1.6 million in Q1 2022 and troughed at -$564000.0 in Q3 2023.
• A 5-year average of $556933.3 and a median of $349000.0 in 2025 frame the typical range for Capital Expenditures.
• The sharpest annual moves came in 2023 and 2025: Capital Expenditures sank 165.66% in 2023, then jumped 1179.17% in 2025.
• Over 5 years, Capital Expenditures stood at $802000.0 in 2022, then sank by 67.08% to $264000.0 in 2023, then fell by 18.94% to $214000.0 in 2024, then jumped by 591.12% to $1.5 million in 2025, then sank by 58.55% to $613000.0 in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered $613000.0, $1.5 million, and $1.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.